Clinical Cancer Research, Vol 4, Issue 3 567-576, Copyright © 1998 by American Association for Cancer Research

ARTICLES

The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression

C Wang, AD Thor, DH Moore 2nd, Y Zhao, R Kerschmann, R Stern, PH Watson and EA Turley
Department of Anatomy and Cell Biology, University of Toronto, and The Hospital for Sick Children, Ontario, Canada.

RHAMM is an oncogene that regulates signaling through ras and controls mitogen-activated protein kinase [extracellular signal-regulated protein kinase (ERK)] expression in embryonic murine fibroblasts. ERK is a dual-specificity kinase that controls expression of proteins relevant to tumorigenesis, proliferation, and motility. To assess whether RHAMM and ERK are involved in human breast tumor progression, we examined RHAMM, ras, and ERK expression in two cohorts of breast cancer patients using reverse transcription-PCR and immunocytochemistry. We show that overexpression of RHAMM in primary tumors of two patient cohorts was significantly prognostic of poor outcome in breast cancer progression. Furthermore, RHAMM overexpression occurred within subsets of tumor cells in the primary tumor, and this staining pattern was associated with lymph node metastases. The metastases exhibited a significantly higher level of staining for RHAMM than did the primary tumor. RHAMM expression strongly correlated with overexpression of both ras and ERK, although overexpression of either of these two signaling molecules was not by itself a prognostic indicator. These results identify a new parameter that is involved in lymph node metastasis of primary breast cancers and suggest that quantification of RHAMM overexpression may be a useful prognostic indicator for breast carcinoma progression.

This article has been cited by other articles:

				I. Zlobec, K. Baker, L. M. Terracciano, and A. Lugli RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis Clin. Cancer Res., June 15, 2008; 14(12): 3798 - 3806. [Abstract] [Full Text] [PDF]

				S. V. Kyosseva, E. N. Harris, and P. H. Weigel The Hyaluronan Receptor for Endocytosis Mediates Hyaluronan-dependent Signal Transduction via Extracellular Signal-regulated Kinases J. Biol. Chem., May 30, 2008; 283(22): 15047 - 15055. [Abstract] [Full Text] [PDF]

				C. A. Maxwell, J. McCarthy, and E. Turley Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J. Cell Sci., April 1, 2008; 121(7): 925 - 932. [Abstract] [Full Text] [PDF]

				D. Manzanares, M.-E. Monzon, R. C. Savani, and M. Salathe Apical Oxidative Hyaluronan Degradation Stimulates Airway Ciliary Beating via RHAMM and RON Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 160 - 168. [Abstract] [Full Text] [PDF]

				S. R. Hamilton, S. F. Fard, F. F. Paiwand, C. Tolg, M. Veiseh, C. Wang, J. B. McCarthy, M. J. Bissell, J. Koropatnick, and E. A. Turley The Hyaluronan Receptors CD44 and Rhamm (CD168) Form Complexes with ERK1,2 That Sustain High Basal Motility in Breast Cancer Cells J. Biol. Chem., June 1, 2007; 282(22): 16667 - 16680. [Abstract] [Full Text] [PDF]

				J. Greiner, M. Schmitt, L. Li, K. Giannopoulos, K. Bosch, A. Schmitt, K. Dohner, R. F. Schlenk, J. R. Pollack, H. Dohner, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches Blood, December 15, 2006; 108(13): 4109 - 4117. [Abstract] [Full Text] [PDF]

				J. Greiner, L. Li, M. Ringhoffer, T. F. E. Barth, K. Giannopoulos, P. Guillaume, G. Ritter, M. Wiesneth, H. Dohner, and M. Schmitt Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia Blood, August 1, 2005; 106(3): 938 - 945. [Abstract] [Full Text] [PDF]

				V. B. Lokeshwar, W. H. Cerwinka, and B. L. Lokeshwar HYAL1 Hyaluronidase: A Molecular Determinant of Bladder Tumor Growth and Invasion Cancer Res., March 15, 2005; 65(6): 2243 - 2250. [Abstract] [Full Text] [PDF]

				C. A. Maxwell, J. J. Keats, A. R. Belch, L. M. Pilarski, and T. Reiman Receptor for Hyaluronan-Mediated Motility Correlates with Centrosome Abnormalities in Multiple Myeloma and Maintains Mitotic Integrity Cancer Res., February 1, 2005; 65(3): 850 - 860. [Abstract] [Full Text] [PDF]

				C. A. Maxwell, E. Rasmussen, F. Zhan, J. J. Keats, S. Adamia, E. Strachan, M. Crainie, R. Walker, A. R. Belch, L. M. Pilarski, et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma Blood, August 15, 2004; 104(4): 1151 - 1158. [Abstract] [Full Text] [PDF]

				C. A. Maxwell, J. J. Keats, M. Crainie, X. Sun, T. Yen, E. Shibuya, M. Hendzel, G. Chan, and L. M. Pilarski RHAMM Is a Centrosomal Protein That Interacts with Dynein and Maintains Spindle Pole Stability Mol. Biol. Cell, June 1, 2003; 14(6): 2262 - 2276. [Abstract] [Full Text] [PDF]

				E. A. Turley, P. W. Noble, and L. Y. W. Bourguignon Signaling Properties of Hyaluronan Receptors J. Biol. Chem., February 8, 2002; 277(7): 4589 - 4592. [Full Text] [PDF]

				P. Auvinen, R. Tammi, J. Parkkinen, M. Tammi, U. Agren, R. Johansson, P. Hirvikoski, M. Eskelinen, and V.-M. Kosma Hyaluronan in Peritumoral Stroma and Malignant Cells Associates with Breast Cancer Spreading and Predicts Survival Am. J. Pathol., February 1, 2000; 156(2): 529 - 536. [Abstract] [Full Text] [PDF]

				S. Kayastha, A. N., F. M., S. Piver, J. Mukkamalla, M. Romero-Guittierez, and B. A. Werness Expression of the Hyaluronan Receptor, CD44S, in Epithelial Ovarian Cancer Is an Independent Predictor of Survival Clin. Cancer Res., May 1, 1999; 5(5): 1073 - 1076. [Abstract] [Full Text] [PDF]